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Background
PAR-2, a G-coupled receptor activated by serine protei-
nases, is widely expressed in the human body and is
involved in inflammation. We have shown that PAR-2
activation in the airways plays a pathogenetic role in
mouse models of asthma. PAR-2 expression is increased
in the epithelium of asthmatic subjects, but its expression
on immune and inflammatory cells of asthmatic indivi-
duals has not been. Severe asthma has different phenotypic
characteristics from mild-moderate disease. In this study
we compared PAR-2 expression on immune cells between
subjects with mild/moderate and severe asthma.
Methods
A total of 36 asthma subjects (24 mild/moderate; 12 severe
by ATS guidelines) were recruited at the University of
Alberta Hospital and peripheral blood obtained. PAR-2
expression was analyzed by flow cytometry and qRT-PCR
in whole blood.
Results
There were no differences in the % of eosinophils, neu-
trophils or CD4+ T cells expressing PAR-2 between
severe and mild/moderate asthmatics. CD14high mono-
cytes were classified as classical (CD14++CD16-) or
intermediate (CD14++CD16+). No difference in total
numbers of either monocyte sub-population was noted
between the two asthma groups. More intermediate
monocytes from patients with severe asthma (33.6
±5.1%) expressed PAR-2 compared to patients with
mild/moderate asthma (22.4±4.0%, p=0.039), but there
was no difference between asthma phenotypes in the
percent of classical monocytes expressing PAR-2
(11.7±2.8% vs. 12.5±2.9%). PAR-2 mRNA expression
was not different between severe and mild/moderate
asthmatics, however, PAR-2 mRNA correlated with total
dose of inhaled steroids and inversely correlated with %
predicted FEV1.
Conclusions
PAR-2 expression is increased on intermediate mono-
cytes in subjects with severe asthma. Intermediate
monocytes are pro-inflammatory and their numbers are
increased in inflammatory diseases. Our data suggest
that PAR-2-mediated activation of intermediate mono-
cytes may play a role in the pathogenesis of severe
asthma, although the effects of PAR-2-mediated activa-
tion of these cells are not known.
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